Schwab Charles Investment Management Inc. Has $59.13 Million Holdings in IDEXX Laboratories, Inc. (IDXX)

Schwab Charles Investment Management Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 380,288 shares of the company’s stock after selling 223,292 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.44% of IDEXX Laboratories worth $59,131,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in IDXX. Strs Ohio increased its stake in IDEXX Laboratories by 0.7% during the 2nd quarter. Strs Ohio now owns 5,929 shares of the company’s stock valued at $957,000 after purchasing an additional 41 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in IDEXX Laboratories by 25.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 3,922 shares of the company’s stock valued at $633,000 after purchasing an additional 792 shares in the last quarter. CIBC Asset Management Inc increased its stake in IDEXX Laboratories by 3.0% during the 2nd quarter. CIBC Asset Management Inc now owns 10,939 shares of the company’s stock valued at $1,766,000 after purchasing an additional 316 shares in the last quarter. Sei Investments Co. increased its stake in IDEXX Laboratories by 94.0% during the 2nd quarter. Sei Investments Co. now owns 39,344 shares of the company’s stock valued at $6,351,000 after purchasing an additional 19,067 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new stake in IDEXX Laboratories during the 2nd quarter valued at about $3,908,000. Institutional investors and hedge funds own 86.80% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $159.30 on Tuesday. IDEXX Laboratories, Inc. has a 12 month low of $113.71 and a 12 month high of $173.01. The company has a market cap of $13,518.90, a P/E ratio of 52.19, a PEG ratio of 2.34 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same period in the previous year, the business posted $0.62 earnings per share. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

A number of analysts have weighed in on IDXX shares. Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research note on Wednesday, August 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Monday, August 21st. Finally, Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $173.67.

In related news, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,529,058.53. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock valued at $16,686,200 over the last quarter. Company insiders own 2.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/05/schwab-charles-investment-management-inc-has-59-13-million-holdings-in-idexx-laboratories-inc-idxx.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit